doi: 10.1001/jamanetworkopen.2026.2450
Kenneth Bilchick, MD, a UVA Health heart rhythm specialist who co-led the study along with Tiago Palmisano, MD, and David Guarraia, MD, explained, The survival curves in all three groups indicated that there was a reduction in the risk of incident atrial fibrillation regardless of whether you gained weight, lost a little weight, or lost a lot of weight. Among the medicines studied, semaglutide showed the strongest association with reduced Afib risk
Impaired cell migration, as a critical factor, affects diabetic wound healing during the proliferative and remodeling phases
Eli Lilly told us: Any product falsely representing itself as a Lilly investigational product not yet approved by the FDA, like retatrutide, may expose patients to potentially serious health risks. It added that it works with regulators and law enforcement to identify and remove fraudulent or unsafe content online and on social media
The ATTAIN-MAINTAIN trial also showed that patients can transition from injectable agents to orforglipron while maintaining their weight loss